PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Antibiotics - Market size and forecast 2018-2023 • Analgesics - Market size and forecast 2018-2023 • Other therapeutics - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 10: MARKET TRENDS PART 11: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 12: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Amryt Pharma • Fresenius • Johnson & Johnson • Novartis • Pfizer PART 13: APPENDIX • Research methodology • List of abbreviations   Exhibit 01: Years in consideration Exhibit 02: Global rare diseases therapeutics market Exhibit 03: Segments of global rare diseases therapeutics market Exhibit 04: Market characteristics Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Product - Market share 2018-2023 (%) Exhibit 18: Comparison by product Exhibit 19: Antibiotics - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Antibiotics - Year-over-year growth 2019-2023 (%) Exhibit 21: Analgesics - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Analgesics - Year-over-year growth 2019-2023 (%) Exhibit 23: Other therapeutics - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Other therapeutics - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by product Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Top 3 countries in North America Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in Europe Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Asia Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in ROW Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Decision framework Exhibit 44: Recent therapeutics that have received orphan drug designation from the US FDA Exhibit 45: Impact of drivers and challenges Exhibit 46: Early phase developmental therapeutics for the treatment of epidermolysis bullosa Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: Amryt Pharma - Vendor overview Exhibit 53: Amryt Pharma - Business segments Exhibit 54: Amryt Pharma - Organizational developments Exhibit 55: Amryt Pharma - Geographic focus Exhibit 56: Amryt Pharma - Segment focus Exhibit 57: Amryt Pharma - Key offerings Exhibit 58: Amryt Pharma - Key customers Exhibit 59: Fresenius - Vendor overview Exhibit 60: Fresenius - Business segments Exhibit 61: Fresenius - Organizational developments Exhibit 62: Fresenius - Geographic focus Exhibit 63: Fresenius - Segment focus Exhibit 64: Fresenius - Key offerings Exhibit 65: Fresenius - Key customers Exhibit 66: Johnson & Johnson - Vendor overview Exhibit 67: Johnson & Johnson - Business segments Exhibit 68: Johnson & Johnson - Organizational developments Exhibit 69: Johnson & Johnson - Geographic focus Exhibit 70: Johnson & Johnson - Segment focus Exhibit 71: Johnson & Johnson - Key offerings Exhibit 72: Johnson & Johnson - Key customers Exhibit 73: Novartis - Vendor overview Exhibit 74: Novartis - Business segments Exhibit 75: Novartis - Organizational developments Exhibit 76: Novartis - Geographic focus Exhibit 77: Novartis - Segment focus Exhibit 78: Novartis - Key offerings Exhibit 79: Novartis - Key customers Exhibit 80: Pfizer - Vendor overview Exhibit 81: Pfizer - Business segments Exhibit 82: Pfizer - Organizational developments Exhibit 83: Pfizer - Geographic focus Exhibit 84: Pfizer - Segment focus Exhibit 85: Pfizer - Key offerings Exhibit 86: Pfizer - Key customers Exhibit 87: Validation techniques employed for market sizing Exhibit 88: List of abbreviations  

Amryt Pharma Fresenius Johnson & Johnson Novartis Pfizer